Zhejiang Orient Gene Biotech Co.,Ltd

Equities

688298

CNE100003RM8

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
27.76 CNY +1.87% Intraday chart for Zhejiang Orient Gene Biotech Co.,Ltd +5.47% -22.37%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zhejiang Orient Gene Biotech's Unit Gets US FDA's Nod to Register Two Products MT
Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zhejiang Orient Gene Biotech Co.,Ltd announces an Equity Buyback for CNY 100 million worth of its shares. CI
Zhejiang Orient Gene Biotech Co.,Ltd authorizes a Buyback Plan. CI
Zhejiang Orient Gene Obtains Veterinary GMP Certificate, Production License MT
Zhejiang Orient Gene Biotech Co.,Ltd(SHSE:688298) dropped from Shanghai Stock Exchange Health Care Sector Index CI
Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Orient Gene Biotech Registers New In Vitro Diagnostic Reagents MT
Zhejiang Orient Gene Biotech Elects Chairman, Vice Chairman MT
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Orient Gene Registers Two Medical Devices in EU, US MT
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
IN BRIEF: Omega Diagnostics receives CD4 deferred consideration AN
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Omega Diagnostics Up 16% With Sale Of Loss-Making CD4 Business MT
ZXBio, Inc. announced that it has received $3.1 million in funding from Zhejiang Orient Gene Biotech Co., Ltd. CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Omega Diagnostics Shares Plunge on $1.4 Million Sale of Loss-making Business to Chinese Biotech MT
MSCI to Add Gree, Three Gorges Renewables, Others to China Indices MT
China Detects First Case of COVID-19 Omicron Strain MT
Chinese COVID-19 Tests Can Detect Omicron Variant, Manufacturers Say MT
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Chart Zhejiang Orient Gene Biotech Co.,Ltd
More charts
Zhejiang Orient Gene Biotech Co., Ltd. is a China-based company principally involved in the research, development, manufacture and sales of in-vitro diagnostic products. The Company's main products are Point of Care Testing (POCT) instant diagnostic reagents, which are mainly used in drug testing, infectious disease testing, eugenic testing, tumor marker testing and cardiac marker testing. The Company also engages in the manufacture and sales of biochemical diagnostic reagents used for dry biochemical diagnostics and biochemical fluid diagnostics. The Company operates its businesses in Mainland China, America, Europe, Asia, Africa and Oceania.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688298 Stock
  4. News Zhejiang Orient Gene Biotech Co.,Ltd
  5. Zhejiang Orient Gene Obtains Veterinary GMP Certificate, Production License